Palvella Therapeutics (PVLA) Cash & Equivalents Growth (3y) (2016 - 2026)
Palvella Therapeutics (PVLA) Cash & Equivalents Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 13.29% |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.63% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -16.07% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -8.88% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 47.78% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Palvella Therapeutics | 1.88 Bn | 1.61 Bn | - | 62.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62.16% |
| Dec 31, 2025 | 14.49% |
| Sep 30, 2025 | -3.07% |
| Jun 30, 2025 | 9.09% |
| Mar 31, 2025 | -3.34% |
| Dec 31, 2024 | -10.79% |
| Sep 30, 2024 | -25.89% |
| Jun 30, 2024 | -45.90% |
| Mar 31, 2024 | -54.61% |
| Dec 31, 2023 | -52.92% |
| Sep 30, 2023 | -12.51% |
| Jun 30, 2023 | 7.41% |
| Mar 31, 2023 | 0.68% |
| Dec 31, 2022 | -14.70% |
| Sep 30, 2022 | 14.86% |
| Jun 30, 2022 | -0.39% |
| Mar 31, 2022 | 17.14% |
| Dec 31, 2021 | 16.30% |
| Sep 30, 2021 | -26.94% |
| Jun 30, 2021 | 21.98% |